NCT00224289View on ClinicalTrials.gov

Effect of Age on Latanoprost 0.005% in Patients With Glaucoma

PHASE4CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Glaucoma

Interventions

DRUG

Latanoprost 0.005%

Latanoprost 0.005% ophthalmic solution QHS 8 weeks

Trial Locations (1)

06510

Yale Eye Center, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Yale University

OTHER